[print friendly]

rosiglitazone (AVANDIA)

• pioglitazone (ACTOS); rosiglitazone (AVANDIA)
  We list these drugs as Do Not Use drugs because they may be less effective than other drugs for diabetes and cause liver damage, weight gain, anemia and heart failure.

• Diabetes Prevention and Treatment [hide all summaries]
  Diets that are very complicated or very different from what you are used to are hard to follow. The American Diabetes Association (ADA) diet is a highly structured plan based on exchange lists. Although it serves its purpose of regulating calorie and sugar intake quite well, the ADA diet may be difficult for older people to use. Successful use of this diet requires considerable time spent planning meal patterns and food portions. Older people often have trouble with this diet because the food lists are long and complicated and require considerable memorization.

• A Review of Exenatide (BYETTA) for Type-2 Diabetes [hide all summaries]
  (November 2009)
  Because exenatide (BYETTA) is a new drug with increasing reports of severe, hospitalization-requiring pancreatitis and offers no significant breakthrough compared to other diabetes drugs, we urge readers not to use it until 2012--seven years after its approval, by which time much more will be known about its dangers.
• Public Citizen Urges Immediate Ban of Rosiglitazone (AVANDIA) [hide all summaries]
  (December 2008)
  On Oct. 30, Public Citizen formally petitioned the Food and Drug Administration (FDA) to immediately ban the dangerous diabetes drug rosiglitazone (AVANDIA) because the drug causes multiple types of serious toxicity.
• Update on Rosiglitazone (AVANDIA): More Strikes Against the Drug [hide all summaries]
  (February 2008)
  Recent updates on this diabetes drug that we have urged our readers not to use for three years are reviewed, including the delisting of the drug by the Veterans Administration because of its dangers and warnings by the Canadian government. We are renewing our call for a ban on the drug in the U.S.
• FDA: Women Taking AVANDIA, ACTOS at Increased Risk of Fractures [hide all summaries]
  (July 2007)
  Yet another reason has arisen to support our several years-old warning not to use the diabetes drugs AVANDIA or ACTOS. Randomized trials of both drugs, compared to other diabetes drugs, showed an increase in fractures in women (not men) using them.
• New Findings: AVANDIA Poses Risks of Heart Attacks, Heart Failure [hide all summaries]
  (July 2007)
  In addition to years-old information about increased heart failure in patients using AVANDIA, that Worst Pills readers have been warned about for years, new evidence has emerged about increased heart attacks as well. The article reviews the evidence for both of these serious problems and why we continue to advise people not to use either AVANDIA or the related drug, ACTOS.
• The Case Against The Diabetes Drug Rosiglitazone (AVANDIA) [hide all summaries]
  (December 2006)
  In addition, there was an almost significant 37 percent excess in the rosiglitazone group of what the authors called cardiovascular events composite, comprised of heart attacks, strokes, cardiovascular deaths, heart failure, the appearance of new angina attacks, and the need for heart surgery such as bypass or angioplasty. You have a greater likelihood of preventing type 2 diabetes by improving your diet and getting a moderate amount of exercise than by taking a prescription drug. The effects of such a change in lifestyle can last a lifetime.
• Some Diabetes Drugs May Cause Vision Problems: Rosiglitazone (AVANDIA) and Macular Edema [hide all summaries]
  (April 2006)
  If you experience visual deterioration while taking rosiglitazone (AVANDIA)or the combination of rosiglitazone with metformin (AVANDAMET), report this potential adverse drug reaction to your physician as soon as possible.
• Dangerous, Inappropriate Prescribing Of Diabetes Drugs Metformin (GLUCOPHAGE), Rosiglitazone (AVANDIA), And Pioglitazone (ACTOS) To Patients With Heart Failure [hide all summaries]
  (September 2003)
  Government-sponsored research published in the July 2, 2003 Journal of the American Medical Association found that the diabetes drugs metformin (GLUCOPHAGE), rosiglitazone (AVANDIA), and pioglitazone (ACTOS) were being prescribed inappropriately to patients with heart failure and that the inappropriate prescribing of these drugs has been increasing over time.

• Life-Threatening Liver Toxicity of Avandia Shown in New Public Citizen Research Published in Peer-Reviewed Medical Journal [hide all summaries]
  WASHINGTON, D.C. - New research by Public Citizen published today in a peer-reviewed medical journal reinforces the case that the diabetes drug Avandia can cause death from liver failure and should be banned immediately by the Food and Drug Administration (FDA).
• Petition to Immediately Ban Diabetes Drug Rosiglitazone (AVANDIA) (HRG Publication #1848) [hide all summaries]
  The Food and Drug Administration (FDA) should immediately ban the dangerous diabetes drug Avandia because it can cause death from liver failure and has many other life-threatening risks that far outweigh its benefits.
• Diabetes Drug Avandia Should Be Removed From the Market, Public Citizen Tells FDA Advisory Committee [hide all summaries]
  The popular type 2 diabetes drug Avandia should be removed from the U.S. market, according to testimony delivered today by Public Citizen before a Food and Drug Administration (FDA) advisory committee panel investigating the medication.
• FDA Knew of Avandia’s Dangers Nearly Five Years Ago, Memo Shows [hide all summaries]
  The Food and Drug Administration (FDA) knew nearly five years ago about the dangers associated with the diabetes drug Avandia, an internal FDA memo shows.
• Evidence Confirms Public Citizen’s Warnings About the Risks of Popular Diabetes Drug Avandia [hide all summaries]
  Statement by Sidney Wolfe, MD, Director of Health Research Group at Public Citizen
• Letter sent to the Lancet on availability of information on thiazolidinediones. (HRG Publication #1534) [hide all summaries]
  However, drug company websites are not the only, and certainly not the best, place to find unpublished data on drugs. Consulting readily available US governmental sources on the internet can lead to different conclusions regarding drug safety and efficacy. Using FDA data sources, we have just completed our own assessment of the thiazolinediones.
• Petition to the Food and Drug Administration requesting that it immediately require labeling for the diabetes drugs troglitazone (Rezulin), rosiglitazone (Avandia) and pioglitazone (Actos)(HRG Publication #1514) [hide all summaries]
  Class efficacy issues include the lack of efficacy compared to previously available drugs, sulfonylureas, and the deterioration of blood sugar levels when patients are switched from other oral anti-diabetic drugs to the glitazones. Safety issues include liver toxicity, effects on heart function, weight gain, edema, anemia, low blood pressure, elevated lipid levels, and possible changes in progesterone levels.

• Improving Public Access to Clinical Trial Information [hide all summaries]
  (September 2007)
  Clinical trials databases can disclose that a trial is taking place and the results of the trial once it is completed. Our international study of such databases shows that only a government-run database is likely to produce a comprehensive, consumer-friendly database.

• Drug Recall for rosiglitazone (AVANDIA) reported in June 24, 2009 FDA Enforcement Report

SHOW secondary search results for rosiglitazone (AVANDIA)